A Phase 4 interventional study of P2Y12 inhibitor and Aspirin in Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF) and Oral Anticoagulation, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 18 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 8 under way, none of them phase 3. Atrial Fibrillation · Insel Gruppe AG, University Hospital Bern.
Among the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 4, and was the 15th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →6 of the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern are open now, in 10 countries. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Belgium, Germany, New Zealand and 3 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–85
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Poland, Switzerland, United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,010 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 208 across the 10 interventional studies, 60 across the 9 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
1 of the studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs. Oral anticoagulants are prescribed to reduce the risk of stroke associated with atrial fibrillation. Antiplatelet substances are prescribed after stent implantation to reduce the risk of adverse cardiac events such as myocardial infarction or stent thrombosis. Treatment with antithrombotic medications can cause bleeding complications, particularly when these substances are combined.
The currently recommended standard strategy consists of treatment with 3 antithrombotic medications for at least 1 week up to one month, followed by treatment with two of these medications for up to 6-12 months after stent implantation. Thereafter, patients usually receive long-term treatment with only one drug, an anticoagulant.
In the monotherapy group of this study, the investigators will investigate a strategy where only one antithrombotic drug will be used at a time. During the first month after stent implantation, the investigators will prescribe an antiplatelet medication, followed by an oral anticoagulant as monotherapy. This strategy might be associated with fewer bleeding complications, while protecting adequately against thrombotic events.
In this study the investigators would like to investigate whether treatment with a single antithrombotic drug ("monotherapy strategy") is associated with benefits compared to the currently recommended combination therapy of antithrombotic medications ("standard-of-care strategy").
Background:
The optimal antithrombotic treatment following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) requiring long-term oral anticoagulation remains a matter of debate. In particular, the appropriate intensity and duration of antithrombotic strategies to prevent ischemic events, while mitigating the risk of bleeding complications in this high bleeding risk population during the early peri-procedural period (within 30 days) and thereafter (from 30 days to 1 year) following drug-eluting stent implantation remains unclear.
Aim:
The investigators aim to assess the safety and efficacy of a P2Y12 inhibitor monotherapy regimen for 1 month followed by DOAC monotherapy long-term versus current standard of care consisting of triple antithrombotic therapy for up to one month (aspirin, P2Y12 inhibitor and DOAC) followed by dual antithrombotic therapy (P2Y12 inhibitor and DOAC) for 6 to 12 months and DOAC monotherapy thereafter, in AF patients undergoing PCI indicated for treatment with a DOAC after drug-eluting stent implantation and followed for a period of 12 months.
Methodology:
This investigator-initiated, multi-center, randomized, open-label, blinded evaluation, international clinical trial in 3010 AF patients with indication for long-term oral anticoagulation who have undergone successful PCI with drug-eluting stent implantation. The study will be conducted at approximately 150 sites across Europe and Brazil. Patients will be randomized to the antithrombotic monotherapy (experimental antithrombotic strategy) or the standard of care strategy (control group) in a 1:1 ratio. Randomization is stratified by site, acute coronary syndrome (ACS) within the previous 6 months and CHA2DS2-VASc score ≥4. Patients randomized to the antithrombotic monotherapy treatment receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) and immediately discontinue aspirin and DOAC. After 1 month, the P2Y12 inhibitor will be stopped and treatment with a commercially available DOAC will be initiated for the duration of 11 months. Patients randomized to the standard of care strategy will initiate triple therapy for up to 1 month followed by dual anti-thrombotic therapy (consisting of P2Y12 inhibitor for a minimum of 6 and up to 12 months plus DOAC for at least 12 months).
Potential significance:
This is the first study investigation the impact of a short course of P2Y12 inhibitor monotherapy up to 1 month, while omitting clopidogrel non-responders, and temporarily omitting OAC, after stent implantation followed by OAC monotherapy in AF patients undergoing PCI. This sequential monotherapy treatment strategy has solid rational and carries potential to balance bleeding against cardiac and cerebral ischemic risks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the monotherapy treatment arm receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, prasugrel oder ticagrelor) and immediately discontinue aspirin and DOAC (or will not re-start DOAC after PCI if treatment was temporarily stopped before). After 1 month, the P2Y12 inhibitor will be stopped and treatment with a commercially available DOAC (at investigator's discretion and dosed according to the instructions for use in patients with atrial fibrillation) will be initiated for the duration of 11 months. After completion of the 12-month study regimen (study visit), the patient will receive antithrombotic therapy according to routine care.
Drug: P2Y12 inhibitor · Drug: DOAC
Patients randomized to the standard of care, receive DOAC for at least 12 months. In addition, aspirin is administered for up to 1 month after PCI at investigator's discretion and one of the available P2Y12 inhibitors (clopidogrel, prasugrel oder ticagrelor at investigator's discretion) is administered for a minimum of 6 months and up to 12 months after PCI. After completion of the 12-month control arm regimen (study visit), the patients will be treated according to routine care.
Drug: P2Y12 inhibitor · Drug: Aspirin · Drug: DOAC
The choice of P2Y12 inhibitor is left at investigator's discretion.
Aspirin is administered for up to 1 month after PCI at investigator's discretion
The choice of DOAC is left at investigator's discretion.
The number of participants with a major adverse cardiac or cerebral events (MACCE), defined as the composite of death from any cause, myocardial infarction, stroke or non-central nervous system (non-CNS) systemic embolism
Time frame: 12 months
The number of participants with a major or clinically relevant non-major bleeding (MCB), defined according to the International Society of Thrombosis and Haemostasis (ISTH) criteria
Time frame: 12 months
The incidence of MACCE or MCB
MACCE, defined as the composite of death from any cause, myocardial infarction, stroke or non-CNS systemic embolism and MCB, defined according to the ISTH criteria
Time frame: 12 months
The incidence of MACCE or MCB
MACCE, defined as the composite of death from any cause, myocardial infarction, stroke or non-CNS systemic embolism and MCB, defined according to the ISTH criteria
Time frame: 15 months
The number of participants with a composite of death from cardiovascular causes, myocardial infarction or stroke
Time frame: 12 months
The number of participants with a composite of death from cardiovascular causes, myocardial infarction or stroke
Time frame: 15 months
The number of participants with a composite of death from cardiovascular causes, myocardial infarction, stroke or non-CNS systemic embolism
Time frame: 12 months
The number of participants with a composite of death from cardiovascular causes, myocardial infarction, stroke or non-CNS systemic embolism
Time frame: 15 months
The number of participants died from cardiovascular or non-cardiovascular causes
Time frame: 12 months
The number of participants died from cardiovascular or non-cardiovascular causes
Time frame: 15 months
The number of participants with a composite of stroke and non-CNS systemic embolism
Time frame: 12 months
The number of participants with a composite of stroke and non-CNS systemic embolism
Time frame: 15 months
The number of participants with any stroke (including ischemic, hemorrhagic and unknown types)
Time frame: 12 months
The number of participants with any stroke (including ischemic, hemorrhagic and unknown types)
Time frame: 15 months
The number of participants with an ischaemic stroke
Time frame: 12 months
The number of participants with an ischaemic stroke
Time frame: 15 months
The number of participants with a hemorrhagic stroke
Time frame: 12 months
The number of participants with a hemorrhagic stroke
Time frame: 15 months
The number of participants with a transient ischemic attack
Time frame: 12 months
The number of participants with a transient ischemic attack
Time frame: 15 months
The number of participants with a composite of definite or probable stent thrombosis
Time frame: 12 months
The number of participants with a composite of definite or probable stent thrombosis
Time frame: 15 months
The number of participants with a definite stent thrombosis
Time frame: 12 months
The number of participants with a definite stent thrombosis
Time frame: 15 months
The number of participants with a hospitalization
Time frame: 12 months
The number of participants with a hospitalization
Time frame: 15 months
The number of participants with a composite of death or hospitalization
Time frame: 12 months
The number of participants with a composite of death or hospitalization
Time frame: 15 months
The number of participants with any target lesion revascularization
Time frame: 12 months
The number of participants with any target lesion revascularization
Time frame: 15 months
The number of participants with any target vessel revascularization
Time frame: 12 months
The number of participants with any target vessel revascularization
Time frame: 15 months
The number of participants with any revascularization
Time frame: 12 months
The number of participants with any revascularization
Time frame: 15 months
The number of all bleeding events, also adjudicated according to Bleeding Academic Research Consortium, Thrombolysis in Myocardial Infarction or Global Use of Strategies to Open Occluded Coronary Arteries scales
The BARC is scaled from 0 to 5, with higher scores indicating worse outcomes, the TIMI from minor to major to fatal bleeding, and the GUSTO from mild to moderate to severe or life-threatening.
Time frame: 12 months
The number of all bleeding events, also adjudicated according to Bleeding Academic Research Consortium, Thrombolysis in Myocardial Infarction or Global Use of Strategies to Open Occluded Coronary Arteries scales
The BARC is scaled from 0 to 5, with higher scores indicating worse outcomes, the TIMI from minor to major to fatal bleeding, and the GUSTO from mild to moderate to severe or life-threatening.
Time frame: 15 months
Transfusion rates both in patients with and/or without clinically detected overt bleeding
Time frame: 12 months
Transfusion rates both in patients with and/or without clinically detected overt bleeding
Time frame: 15 months
The number of participants with a major adverse cardiac or cerebral events (MACCE), defined as the composite of death from any cause, myocardial infarction, stroke or non-central nervous system (non-CNS) systemic embolism
Time frame: 15 months
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 48 months after the start.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 48 months is close to that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: P2Y12 Inhibitor
Insel Gruppe AG, University Hospital Bern →